
Darzalex Faspro-Based Quadruplet Regimen Approved for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible
Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for the treatment of adult patients…
Read more








